Yuanmei Lou
Overview
Explore the profile of Yuanmei Lou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
806
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Li S, Yao Q, Du N, Fu X, Lou Y, et al.
World J Surg Oncol
. 2020 Jul;
18(1):150.
PMID: 32620130
Background: Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab...
2.
Chafe S, Lou Y, Sceneay J, Vallejo M, Hamilton M, McDonald P, et al.
Cancer Res
. 2015 Jan;
75(6):996-1008.
PMID: 25623234
The mobilization of bone marrow-derived cells (BMDC) to distant tissues before the arrival of disseminated tumor cells has been shown preclinically to facilitate metastasis through the establishment of metastatic niches....
3.
Touisni N, Maresca A, McDonald P, Lou Y, Scozzafava A, Dedhar S, et al.
J Med Chem
. 2011 Nov;
54(24):8271-7.
PMID: 22077347
A series of 7-substituted coumarins incorporating various glycosyl moieties were synthesized and investigated for the inhibition of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). These coumarins were very weak...
4.
Lou Y, McDonald P, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al.
Cancer Res
. 2011 Mar;
71(9):3364-76.
PMID: 21415165
Carbonic anhydrase IX (CAIX) is a hypoxia and HIF-1-inducible protein that regulates intra- and extracellular pH under hypoxic conditions and promotes tumor cell survival and invasion in hypoxic microenvironments. Interrogation...
5.
Pacchiano F, Carta F, McDonald P, Lou Y, Vullo D, Scozzafava A, et al.
J Med Chem
. 2011 Mar;
54(6):1896-902.
PMID: 21361354
A series of ureido-substituted benzenesulfonamides was prepared that showed a very interesting profile for the inhibition of several human carbonic anhydrases (hCAs, EC 4.2.1.1), such as hCAs I and II...
6.
Auf dem Keller U, Bellac C, Li Y, Lou Y, Lange P, Ting R, et al.
Cancer Res
. 2010 Aug;
70(19):7562-9.
PMID: 20729277
Matrix metalloproteinases (MMP), strongly associated pathogenic markers of cancer, have undergone extensive drug development programs. Marimastat, a noncovalent MMP inhibitor, was conjugated with FITC to label cellular metalloproteinase cancer targets...
7.
Lou Y, Preobrazhenska O, Auf dem Keller U, Sutcliffe M, Barclay L, McDonald P, et al.
Dev Dyn
. 2008 Sep;
237(10):2755-68.
PMID: 18773493
Epithelial-mesenchymal transition (EMT) has been linked to metastatic propensity. The 4T1 tumor is a clinically relevant model of spontaneous breast cancer metastasis. Here we characterize 4T1-derived cell lines for EMT,...
8.
Lou Y, Basha G, Seipp R, Cai B, Chen S, Moise A, et al.
Clin Cancer Res
. 2008 Mar;
14(5):1494-501.
PMID: 18316574
Purpose: Tpn is a member of the MHC class I loading complex and functions to bridge the TAP peptide transporter to MHC class I molecules. Metastatic human carcinomas often express...
9.
Lou Y, Seipp R, Cai B, Chen S, Vitalis T, Choi K, et al.
Vaccine
. 2007 Jan;
25(12):2331-9.
PMID: 17229499
Despite continued progress in understanding the pathophysiology of tumours, curative therapeutic options are still lacking for the metastatic form of the disease. One approach that has gathered considerable interest is...
10.
Lou Y, Vitalis T, Basha G, Cai B, Chen S, Choi K, et al.
Cancer Res
. 2005 Sep;
65(17):7926-33.
PMID: 16140964
A wide variety of human carcinomas have low expression of tumor-associated antigen presentation in the context of MHC class I antigens due to defects in the antigen presentation pathway. This...